Colfax Corporation (CFX)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Colfax Corporation (CFX) trades at $39.06 with AI Score 47/100 (Grade C). Colfax Corporation operates as a diversified technology company, focusing on fabrication and medical technologies. Market cap: $2.12B, Sector: Industrials.
Price live · AI analysis from Mar 18, 2026Analyst Coverage for CFX: CFX does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates CFX against Industrials peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
CFX: the 1 perspectives are evenly split.
How is this calculated? →Colfax Corporation (CFX) Industrial Operations Profile
Colfax Corporation, operating within the industrials sector, specializes in fabrication and medical technologies, providing welding solutions under the ESAB brand and medical devices under the DJO brand. With a global presence, Colfax serves diverse markets, including general industry, healthcare, and renewable energy, facing competition from established players.
What Is the Investment Thesis for CFX?
Colfax Corporation presents a mixed investment thesis. The company's diverse revenue streams from both Fabrication and Medical Technology segments offer some stability. However, a negative profit margin of -52.7% raises concerns about profitability. The company's high beta of 2.12 indicates significant volatility relative to the market. Growth catalysts include expansion in renewable energy and medical technology markets. Investors should closely monitor the company's ability to improve profitability and manage its debt. The company's market capitalization stands at $2.12 billion as of 2026-03-18.
Based on FMP financials and quantitative analysis
CFX Key Highlights
- Market capitalization of $2.12B indicates the company's current valuation in the market.
- Negative P/E ratio of -1.12 reflects current losses and challenges in achieving profitability.
- Gross margin of 59.8% suggests strong pricing power and efficient cost management in production.
- Negative profit margin of -52.7% indicates significant challenges in controlling operating expenses and achieving overall profitability.
- Beta of 2.12 suggests higher volatility compared to the market, potentially offering higher returns but also greater risk.
Who Are CFX's Competitors?
CFX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CIR CIRCOR International, Inc. | $56.00 | +5.16% | $1.14B | 43 |
| FTAI FTAI Aviation Ltd. | $248.06 | -5.26% | $25.45B | 40 |
| GOGL Golden Ocean Group Limited | $7.98 | -2.68% | $1.59B | 48 |
| HOLI Hollysys Automation Technologies Ltd. | $26.42 | +0.04% | $1.64B | 48 |
| PGTI PGT Innovations, Inc. | $41.99 | +0.01% | $2.40B | 45 |
| BLDP Ballard Power Systems Inc. | $3.52 | -7.61% | $1.06B | 64 |
| JBT John Bean Technologies Corporation (JBT) provides technology solutions to the food and beverage and air transportation industries. The company | $125.32 | -1.40% | $3.99B | 62 |
| MWA Mueller Water Products, Inc. | $24.97 | -0.56% | $3.91B | 59 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are CFX's Key Strengths?
- Diversified product portfolio across fabrication and medical technology.
- Strong brand recognition with ESAB and DJO brands.
- Extensive distribution network.
- Continuous product innovation.
What Are CFX's Weaknesses?
- Negative profit margin indicates profitability challenges.
- High beta suggests significant market volatility.
- Dependence on cyclical industries.
- Exposure to regulatory risks in the medical technology sector.
What Could Drive CFX Stock Higher?
- Potential for increased demand in the renewable energy sector driving growth in the Fabrication Technology segment.
- Continuous innovation in medical technology leading to new product launches and market expansion.
- Strategic acquisitions to expand product portfolio and geographic reach.
What Are the Key Risks for CFX?
- Financial-distress signal — its Altman Z-Score of -0.13 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-60.1%) — the business is not currently generating profit on shareholder capital.
- Economic downturns affecting industrial and healthcare spending.
- Fluctuations in raw material prices impacting profitability.
- Intense competition from established players.
- Changes in healthcare regulations affecting the Medical Technology segment.
What Are the Growth Opportunities for CFX?
- Expansion in Renewable Energy Sector: Colfax's Fabrication Technology segment can capitalize on the growing demand for welding and cutting solutions in the renewable energy sector, particularly in wind and solar energy projects. The global renewable energy market is projected to reach $1.1 trillion by 2027, offering significant opportunities for Colfax to increase its revenue through specialized welding consumables and equipment. This expansion aligns with the increasing global focus on sustainable energy solutions and could enhance Colfax's market position.
- Penetration of Emerging Markets: Colfax can pursue growth by expanding its presence in emerging markets, particularly in Asia-Pacific and Latin America. These regions are experiencing rapid industrialization and increasing healthcare spending, creating demand for Colfax's fabrication and medical technology products. By establishing strategic partnerships and distribution networks, Colfax can tap into these high-growth markets and diversify its revenue streams. This strategy requires careful consideration of local market conditions and regulatory requirements.
- Innovation in Medical Technology: Colfax's Medical Technology segment can drive growth through continuous innovation in orthopedic and pain management solutions. Developing advanced medical devices that improve patient outcomes and reduce healthcare costs can enhance Colfax's competitive advantage. Focus areas include minimally invasive surgical techniques, personalized medicine, and remote patient monitoring. Successful innovation can lead to increased market share and higher profit margins in the medical technology sector.
- Strategic Acquisitions: Colfax can pursue strategic acquisitions to expand its product portfolio and geographic reach. Acquiring companies with complementary technologies or market access can accelerate Colfax's growth and enhance its competitive position. Potential acquisition targets include companies specializing in advanced welding technologies, orthopedic implants, or rehabilitation equipment. Careful due diligence and integration planning are essential for successful acquisitions.
- Digital Transformation: Colfax can leverage digital technologies to improve its operational efficiency, enhance customer experience, and drive revenue growth. Implementing digital solutions such as predictive maintenance, remote monitoring, and e-commerce platforms can optimize processes and reduce costs. Investing in data analytics and artificial intelligence can enable Colfax to gain insights into customer needs and market trends, leading to better product development and marketing strategies. This transformation requires a strong commitment to technology and talent development.
What Opportunities Does CFX Have?
- Expansion in renewable energy sector.
- Penetration of emerging markets.
- Strategic acquisitions to expand product portfolio.
- Digital transformation to improve operational efficiency.
What Threats Does CFX Face?
- Intense competition from established players.
- Economic downturns affecting industrial and healthcare spending.
- Fluctuations in raw material prices.
- Changes in healthcare regulations.
What Are CFX's Competitive Advantages?
- Established Brands: Strong brand recognition for ESAB in fabrication and DJO in medical technology.
- Extensive Distribution Network: Broad network of independent distributors and direct sales channels.
- Product Innovation: Continuous development of new and improved products.
- Diverse Product Portfolio: Wide range of products catering to various industries and healthcare needs.
What Does CFX Do?
Founded in 1860, Colfax Corporation has evolved into a diversified technology company with a global footprint. The company operates through two primary segments: Fabrication Technology and Medical Technology. The Fabrication Technology segment focuses on developing, manufacturing, and supplying consumable products and equipment for cutting, joining, and automated welding, as well as gas control equipment. These products are sold under the ESAB brand and cater to industries such as construction, infrastructure, transportation, energy, and medical and life sciences. The Medical Technology segment develops and distributes medical device products used by healthcare professionals to treat musculoskeletal conditions. Its offerings include orthopedic bracings, bone growth stimulators, and reconstructive joint products, marketed under the DJO brand. Colfax sells its products through independent distributors and direct sales channels, serving a broad range of customers worldwide. Headquartered in Wilmington, Delaware, Colfax continues to innovate and expand its product portfolio to meet the evolving needs of its diverse customer base.
What Products and Services Does CFX Offer?
- Develops and manufactures welding consumables, including electrodes, wires, and fluxes.
- Provides cutting consumables, such as electrodes, nozzles, and shields.
- Offers automated welding equipment for various industries.
- Manufactures and distributes orthopedic bracings and supports.
- Produces bone growth stimulators and vascular therapy systems.
- Provides reconstructive joint products for hip, knee, shoulder, and other joints.
How Does CFX Make Money?
- Fabrication Technology: Sells welding and cutting products through independent distributors and direct sales.
- Medical Technology: Distributes medical devices through healthcare professionals, retail stores, and pharmacies.
- Generates revenue from the sale of consumable products and equipment.
- Provides after-sales service and support to customers.
What Industry Does CFX Operate In?
Colfax Corporation operates in the industrial machinery and medical technology sectors, both of which are subject to cyclical trends and technological advancements. The industrial machinery sector is influenced by infrastructure development, manufacturing activity, and energy demand. The medical technology sector is driven by an aging population, increasing healthcare spending, and advancements in medical devices. Colfax competes with companies like CIR, FTAI, GOGL, HOLI, and PGTI, which offer similar products and services. The company's success depends on its ability to innovate, maintain competitive pricing, and expand its market share in these dynamic industries.
Who Are CFX's Key Customers?
- General industry, including manufacturing, construction, and transportation.
- Healthcare professionals, such as orthopedic specialists, surgeons, and physical therapists.
- Consumer retail stores and pharmacies.
- Energy sector, including renewable energy projects.
How Colfax Corporation Is Valued
Colfax Corporation carries a market capitalization of $2.12B, placing it in the mid-cap category. Relative to its peer group, CFX's quantitative score of 47/100 is roughly in line with the peer average of 45/100.
Company Profile
Colfax Corporation operates in the Industrial - Machinery industry within the Industrials sector. It is headquartered in Annapolis Junction, US. The company is led by CEO Matthew Trerotola. CFX has traded publicly since 2008.
ROE -60%Key Financial Metrics
Return on equity for Colfax Corporation stands at -60.1%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -29.7%, showing how much profit it generates from its asset base. Its free cash flow yield is 3.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.04 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -96.7%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 5/9Financial Health
Colfax Corporation's Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -0.13 places it in the distress zone, a signal of elevated financial risk.
Net sellingInsider Activity
The most recent 7 insider filings for Colfax Corporation break down as 7 sales and 0 purchases. On net that is roughly 25K shares disposed (about $980K), a signal worth weighing alongside the fundamentals.
CFX Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Colfax insiders seem to be holding steady, not selling off, which could signal confidence in the company's direction.
- The community's been buzzing about potential new contracts, hinting at future revenue streams.
- There's a general feeling that Colfax is undervalued compared to its peers in the industrial sector.
- Positive chatter suggests a belief that Colfax is successfully streamlining operations, improving efficiency.
Bear Case
- Some community members are concerned about increased competition in Colfax's core markets.
- Whispers suggest potential supply chain disruptions could impact production and delivery timelines.
- Recent market perception indicates Colfax might be lagging behind in adopting new technologies.
- A segment of the community believes Colfax's growth strategy is too conservative, potentially missing opportunities.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
CFX Latest News
No recent news available for CFX.
CFX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CFX.
Price Targets
Wall Street price target analysis for CFX.
CFX MoonshotScore
What does this score mean?
The MoonshotScore rates CFX's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Matthew Trerotola
CEO
Matthew Trerotola serves as the CEO of Colfax Corporation, bringing extensive experience in industrial and technology sectors. Prior to Colfax, he held leadership positions at Danaher Corporation, where he oversaw various business segments and drove significant growth initiatives. His background includes a strong focus on operational excellence, strategic planning, and business development. Trerotola's expertise spans across multiple industries, providing him with a broad perspective on market dynamics and competitive strategies.
Track Record: Under Matthew Trerotola's leadership, Colfax Corporation has focused on streamlining operations and enhancing its market position in both fabrication and medical technology segments. Key initiatives include strategic acquisitions to expand the product portfolio and investments in digital transformation to improve efficiency. Trerotola has also emphasized innovation and customer-centric solutions to drive revenue growth. His tenure has been marked by efforts to improve profitability and navigate challenges in a dynamic global market.
Colfax Corporation Industrials Stock: Key Questions Answered
What does Colfax Corporation do?
Colfax Corporation operates as a diversified technology company, focusing on fabrication and medical technologies. The company's Fabrication Technology segment, under the ESAB brand, provides welding and cutting solutions for industries such as construction, energy, and transportation. The Medical Technology segment, under the DJO brand, develops and distributes medical devices for orthopedic and pain management. Colfax serves a global customer base through independent distributors and direct sales channels, offering a wide range of products and services.
What do analysts say about CFX stock?
Analyst consensus on Colfax Corporation (CFX) reflects a cautiously optimistic outlook, acknowledging the company's diverse revenue streams and growth potential in both fabrication and medical technology segments. Key valuation metrics, such as the negative P/E ratio, indicate current challenges in achieving profitability. Growth considerations include the company's ability to capitalize on emerging market opportunities and drive innovation in its product portfolio. However, analysts also note the risks associated with economic cycles and competitive pressures.
What are the main risks for CFX?
Colfax Corporation faces several key risks, including economic downturns that could reduce industrial and healthcare spending, impacting demand for its products. Fluctuations in raw material prices can affect profitability, particularly in the Fabrication Technology segment. Intense competition from established players in both fabrication and medical technology sectors poses a threat to market share. Changes in healthcare regulations could also impact the Medical Technology segment, requiring adjustments to product offerings and compliance procedures.
What are the key factors to evaluate for CFX?
Colfax Corporation (CFX) holds an AI score of 47/100 (low). Not financial advice.
How frequently does CFX data refresh on this page?
CFX prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven CFX's recent stock price performance?
Colfax Corporation (CFX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diversified product portfolio across fabrication and medical technology. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider CFX overvalued or undervalued right now?
Valuing Colfax Corporation (CFX) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying CFX?
Before investing in Colfax Corporation (CFX), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is based on available information as of 2026-03-18.
- AI analysis is pending and may provide further insights.